Hairstetics

Company Overview

Snapshot

Founded in April 2010 by Boaz Shenhav and Dvir Keren, Hairstetics operates with 1-10 employees. The company has raised $7.42 million across 5 funding rounds, with Peregrine Ventures participating as a lead investor in one of its rounds. In October 2025, Hairstetics secured a €2 million investment from Cutia Therapeutics, granting them exclusive marketing rights in China for their synthetic hair implant treatment.

Business overview

Hairstetics is a Health Tech & Life Sciences company developing state-of-the-art hair implants. Its core product, the Hairstetics Hair Implant Device, is a multiple-hair implantation device with an anchoring system designed to provide a non-surgical, no-downtime treatment for Alopecia and hair loss. The company primarily targets women with androgenetic alopecia, with plans to expand to the broader alopecia-affected population. Hairstetics offers user-friendly devices for physicians, streamlining the hair transplantation process compared to existing solutions.

Strategic signal

In October 2025, Hairstetics announced a strategic €2 million investment from Cutia Therapeutics, which includes exclusive marketing rights for their minimally invasive synthetic hair implant treatment in China. This partnership is a significant growth catalyst, enabling Hairstetics to tap into the rapidly expanding Chinese hair loss therapeutics market and signals strong international validation for their innovative medical aesthetics solution.

Company Intelligence Q&A

What significant investment did Hairstetics secure in October 2025?

In October 2025, Hairstetics secured a €2 million investment from Cutia Therapeutics, granting the Chinese public company exclusive rights to market Hairstetics' solution in China and Hong Kong. This investment is aimed at expanding Hairstetics' market presence in the region.

What is Hairstetics' core product for hair restoration?

Hairstetics developed the Hairstetics Hair Implant Device, a multiple-hair implantation device with an anchoring system. This product provides a minimally invasive, non-surgical treatment for Alopecia and hair loss, particularly targeting women with androgenetic alopecia.

Which investor has frequently participated in Hairstetics' funding rounds?

Peregrine Ventures has been a recurring investor in Hairstetics' funding rounds, including a follow-on investment in November 2023 and another in September 2022. Peregrine Ventures also led a funding round in June 2018.

In which countries is Hairstetics' hair restoration procedure currently available?

As of May 2023, Hairstetics' hair restoration procedure is available in Israel, Brazil, France, Switzerland, and Belgium. The company has plans for future expansion into the American market, pending FDA approval.

What recognition did Hairstetics receive in September 2021?

In September 2021, Hairstetics won the first prize for innovation at the IMCAS annual international conference for aesthetic medicine. This award recognized their groundbreaking technology for synthetic hair injection and its potential to revolutionize hair restoration.